{"schema_version":"1.0","type":"article","title":"營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？","url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.md","lang":"zh-Hant","date":"2026-08-17","publish_at":"2026-08-17T08:00:00+08:00","updated_at":"2026-08-17","category":"商業分析系列","topic":"商業分析系列","tags":["Iovance","Amtagvi","TIL","癌症細胞療法","黑色素瘤","細胞治療","天明製藥"],"summary":"Iovance 的 Amtagvi 第二季營收明顯反彈，但真正要驗證的不是 TIL 是否有療效，而是個人化細胞療法能否被做成可複製、可支付、可放大的醫療服務。","key_points":[],"facts":[],"sections":["參考資料","免責聲明"],"references":[{"title":"[Iovance 2026 Q2 results press release]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_ex99-1.htm"},{"title":"[Iovance 2026 Q2 Form 10-Q]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926091716/iova-20260630x10q.htm"},{"title":"[Iovance 2026 Q1 results press release]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_ex99-1.htm"},{"title":"[FDA Amtagvi product page]","source":"","date":"","url":"https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi"},{"title":"[FDA approval announcement for Amtagvi]","source":"","date":"","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-to-treat-patients-with-unresectable-or-metastatic-melanoma"},{"title":"[Amtagvi prescribing information]","source":"","date":"","url":"https://www.fda.gov/media/176417/download"},{"title":"[FDA Summary Basis for Regulatory Action]","source":"","date":"","url":"https://www.fda.gov/media/176951/download"},{"title":"[ClinicalTrials.gov NCT05727904]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05727904"},{"title":"[ClinicalTrials.gov NCT02360579]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT02360579"},{"title":"[TPEx emerging stock disclosure for Timing Pharma]","source":"","date":"","url":"https://wwwov.tpex.org.tw/storage/eb_data/11412/11400105781.html"},{"title":"[Timing Pharma cell therapy services]","source":"","date":"","url":"https://www.timing-pharmacy.com/service"},{"title":"查證截止日：2026 年 8 月 18 日。","source":"","date":"","url":""}],"images":[{"alt":"圖1｜Iovance 第二季營收反彈與 Amtagvi 商業化進展圖解","url":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/figure-01.png"},{"alt":"圖2｜TIL 療法從腫瘤取樣、製造、輸注到支付的一條接力流程","url":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/figure-02.png"},{"alt":"圖3｜Amtagvi 從工廠到病房的四個營運堵點","url":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/figure-03.png"},{"alt":"圖4｜個人化癌症細胞療法下一個十年的勝負關鍵","url":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-17）。營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？。https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-17-iovance-amtagvi-til-commercialization-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}